AmCad BioMed Corporation (TPEX:4188)

Taiwan · Delayed Price · Currency is TWD

15.40

-0.65 (-4.05%)

Oct 30, 2026, 1:30 PM CST

Market Cap	975.33M -3.7%
Revenue (ttm)	28.60M -34.4%
Net Income	-52.66M
EPS	-0.83
Shares Out	63.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	458,104
Open	15.90
Previous Close	16.05
Day's Range	15.20 - 16.20
52-Week Range	9.06 - 18.85
Beta	0.43
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2008

Employees 34

Stock Exchange Taipei Exchange

Ticker Symbol 4188

Full Company Profile

Financial Performance

In 2025, AmCad BioMed's revenue was 30.44 million, a decrease of -42.69% compared to the previous year's 53.11 million. Losses were -55.72 million, 10.2% more than in 2024.

Financial Statements